Q1 EPS Estimates for Legend Biotech Reduced by William Blair

Legend Biotech Co. (NASDAQ:LEGN) – Analysts at William Blair dropped their Q1 2025 earnings per share (EPS) estimates for Legend Biotech in a report issued on Wednesday, March 12th. William Blair analyst S. Corwin now expects that the company will post earnings per share of ($0.40) for the quarter, down from their previous forecast of ($0.19). The consensus estimate for Legend Biotech’s current full-year earnings is ($1.31) per share. William Blair also issued estimates for Legend Biotech’s Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.85) EPS, Q1 2026 earnings at $0.03 EPS, Q2 2026 earnings at $0.16 EPS, Q3 2026 earnings at $0.26 EPS, Q4 2026 earnings at $0.33 EPS and FY2026 earnings at $0.79 EPS.

LEGN has been the subject of a number of other reports. Morgan Stanley dropped their price objective on Legend Biotech from $82.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $83.00 price objective on shares of Legend Biotech in a research note on Monday, December 9th. Piper Sandler reaffirmed an “overweight” rating and issued a $78.00 price objective on shares of Legend Biotech in a research note on Monday, December 30th. HC Wainwright lifted their price objective on Legend Biotech from $73.00 to $75.00 and gave the company a “buy” rating in a research note on Wednesday, March 12th. Finally, Guggenheim reiterated a “neutral” rating on shares of Legend Biotech in a report on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $79.00.

Legend Biotech Trading Down 0.2 %

Shares of NASDAQ LEGN opened at $37.88 on Monday. Legend Biotech has a twelve month low of $30.17 and a twelve month high of $64.28. The company has a current ratio of 4.98, a quick ratio of 4.90 and a debt-to-equity ratio of 0.27. The stock has a fifty day simple moving average of $35.83 and a 200-day simple moving average of $40.47. The stock has a market capitalization of $6.92 billion, a PE ratio of -39.87 and a beta of 0.19.

Legend Biotech (NASDAQ:LEGN) last posted its earnings results on Tuesday, March 11th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.46. The company had revenue of $186.50 million during the quarter, compared to analysts’ expectations of $179.00 million. Legend Biotech had a negative return on equity of 29.69% and a negative net margin of 66.92%. The firm’s quarterly revenue was up 134.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.40) earnings per share.

Institutional Trading of Legend Biotech

A number of institutional investors have recently bought and sold shares of the business. Lansforsakringar Fondforvaltning AB publ purchased a new stake in Legend Biotech during the 4th quarter worth about $914,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Legend Biotech during the 4th quarter worth about $776,000. Polar Asset Management Partners Inc. lifted its holdings in Legend Biotech by 65.8% during the 4th quarter. Polar Asset Management Partners Inc. now owns 24,638 shares of the company’s stock worth $802,000 after buying an additional 9,779 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in Legend Biotech during the 4th quarter worth about $56,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Legend Biotech by 36.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 136,438 shares of the company’s stock worth $4,440,000 after buying an additional 36,181 shares during the last quarter. 70.89% of the stock is owned by hedge funds and other institutional investors.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).